Inhibikase Therapeutics Inc. (IKT)
NASDAQ · Healthcare
Inhibikase Therapeutics Inc. Long Term Debt 2020–2024
Inhibikase Therapeutics Inc. annual long term debt history from 2021 to 2023. Long term debt refers to financial obligations that are due more than one year in the future.
- Inhibikase Therapeutics Inc. long term debt as of December 31, 2023: 381,784, a 53.38% increase year-over-year.
- Inhibikase Therapeutics Inc. long term debt for 2023 were 381,784, a 53.38% increase from 2021.
- Inhibikase Therapeutics Inc. long term debt for 2021 were 248,911.
Long Term Debt
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Inhibikase Therapeutics Inc. Annual Long Term Debt (Millions of US $) | |
|---|---|
| 2023 | $0 |
| 2021 | $0 |
Inhibikase Therapeutics Inc. Long Term Debt — FAQ
Inhibikase Therapeutics Inc. (IKT) long term debt over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see IKT's long term debt history?
The chart and table above show Inhibikase Therapeutics Inc.'s long term debt by year and by quarter, including the growth rate.